-
Capital, M&A & Industry Strategy3 weeks agoArgenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart
Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the...
-
Capital, M&A & Industry Strategy3 weeks agoBig Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset
Matchpoint’s lead asset is the oral T cell modulator MPT-062, which the biotech plans to advance into clinical development for autoimmune and inflammatory conditions next year.
-
Capital, M&A & Industry Strategy3 weeks agoBeyond equity: Why venture debt is reshaping European biotech
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture...
-
Capital, M&A & Industry Strategy3 weeks agoBiohub raises $1.8bn for its ‘virtual biology’ initiative
Just months after launching an open-source 'virtual biology' platform, Biohub has raised $1.8 billion in backing for the AI-powered initiative.
-
Capital, M&A & Industry Strategy3 weeks agoQ3 layoffs down YOY, with 90% fewer biopharma employees affected
Big Pharma companies including Bristol Myers Squibb, Johnson & Johnson and Novartis are among those that made or planned layoffs in Q3. Those cuts could affect...
-
Capital, M&A & Industry Strategy3 weeks agoLayoffs at Caribou as two CAR Ts scrapped
BIOCENTURY | MANAGEMENT TRACKSLAYOFFS AT CARIBOU AS TWO CAR TS SCRAPPEDPlus: David Liu joining Vir as CMO — and more
-
Capital, M&A & Industry Strategy3 weeks agoSTAT+: Forbion raises $2.6 billion, its largest fundraise to date
Forbion, a prominent European venture capital firm, said it has raised $2.6 billion, its largest fundraise to date and one of the largest in the region in...
-
Capital, M&A & Industry Strategy3 weeks agoFrom strong science to mature companies: The next test for Spanish biotech
Look into Spain's biotech, an ecosystem that has matured and transforms promissing science into ventures but faces challenges in later stages. The post From strong science...
-
Capital, M&A & Industry Strategy3 weeks agoBiotech VC Forbion raises record $2.6B to support 30 ‘high-potential’ companies
Forbion participated in the November 2025 series B round of Gate Bioscience, which earlier this week inked an up to $870 million deal extension with Eli...
-
Capital, M&A & Industry Strategy3 weeks agoDoudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up
Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
